{"schema_version":"1","generated_at":"2026-10-28T12:21:46.361Z","data_as_of":null,"url":"https://www.findmykol.com/kol/yuliya-linhares","json_url":"https://www.findmykol.com/kol/yuliya-linhares/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"yuliya-linhares","name":"Yuliya Linhares","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Baptist Hospital of Miami","institution_url":"https://www.findmykol.com/institution/baptist-hospital-of-miami","city":"Miami","state":"FL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1225299563","orcid":"0000-0001-9911-7003","openalex":"A5005446862"},"summary":"Yuliya Linhares is an Oncology physician affiliated with Baptist Hospital of Miami. OpenAlex indexes 78 publications with 514 citations (h-index 11); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":78,"cited_by_count":514,"h_index":11,"latest_activity_year":2026,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT05681195","title":"Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Baptist Health South Florida","source_url":"https://clinicaltrials.gov/study/NCT05681195","trial_url":"https://www.findmykol.com/trial/NCT05681195"},{"nct":"NCT01235793","title":"The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Cedars-Sinai Medical Center","source_url":"https://clinicaltrials.gov/study/NCT01235793","trial_url":"https://www.findmykol.com/trial/NCT01235793"}],"source":"trials"},"payments":{"company_count":30,"program_years":{"first":2021,"last":null},"rows_total":52,"shown":3,"withheld":49,"rows":[{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2025,"amount_usd":4775,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1225299563"},{"payer":"Acrotech Biopharma Inc.","program_year":2025,"amount_usd":4031.34,"payment_count":7,"source_url":"https://openpaymentsdata.cms.gov/search?query=1225299563"},{"payer":"Genmab U.S., Inc.","program_year":2025,"amount_usd":3191.65,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1225299563"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1225299563","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Single Center Retrospective Comparison of Post-Transplant Cyclophosphamide and Standard Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Transplantation","year":2026,"journal":"Transplantation Proceedings","source_url":"https://doi.org/10.1016/j.transproceed.2025.12.008","status":"verified"},{"title":"Reducing Resource Utilization and Costs through a Revised Stem Cell Mobilization and Collection Algorithm in Multiple Myeloma","year":2026,"journal":"Biology of Blood and Marrow Transplantation","source_url":"https://doi.org/10.1016/j.jtct.2025.12.313","status":"verified"},{"title":"Novel Therapies in Primary Central Nervous System Lymphoma","year":2025,"journal":"Clinical Pharmacology Advances and Applications","source_url":"https://doi.org/10.2147/cpaa.s501065","status":"verified"},{"title":"ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.tps7085","status":"verified"},{"title":"Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab.","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.7040","status":"verified"}],"source":"works"},"contact":{"address_1":"8900 N KENDALL DR","address_2":"MIAMI CANCER INSTITUTE","city":"Miami","state":"FL","zip":"331762118","phone":"786-596-2000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1225299563","source":"identity"},"similar":[{"name":"Lyle Feinstein","slug":"lyle-feinstein","institution":"Baptist Hospital of Miami","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/lyle-feinstein","json_url":"https://www.findmykol.com/kol/lyle-feinstein/profile.json"},{"name":"Horacio Asbun","slug":"horacio-asbun","institution":"Baptist Hospital of Miami","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/horacio-asbun","json_url":"https://www.findmykol.com/kol/horacio-asbun/profile.json"},{"name":"Ricardo Cury","slug":"ricardo-cury","institution":"Baptist Hospital of Miami","specialty":"Diagnostic Radiology","url":"https://www.findmykol.com/kol/ricardo-cury","json_url":"https://www.findmykol.com/kol/ricardo-cury/profile.json"},{"name":"Atulya Khosla","slug":"atulya-khosla","institution":"Baptist Hospital of Miami","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/atulya-khosla","json_url":"https://www.findmykol.com/kol/atulya-khosla/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":49,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2019-07-22","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}